Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COINNYSE:CVNANYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOINCoinbase Global$157.28-2.0%$224.58$142.58▼$349.75$39.93B3.659.70 million shs13.20 million shsCVNACarvana$167.59+3.1%$221.99$67.61▼$292.84$35.73B3.613.99 million shs6.91 million shsJNJJohnson & Johnson$150.47-1.8%$159.70$140.68▼$169.99$362.60B0.497.81 million shs18.08 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOINCoinbase Global-2.04%-8.68%-27.67%-40.50%-34.71%CVNACarvana+3.11%-19.87%-10.94%-15.64%+99.90%JNJJohnson & Johnson-1.67%-9.30%-9.80%+2.92%-1.26%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOINCoinbase Global4.3437 of 5 stars4.32.00.00.02.54.23.1CVNACarvana4.4061 of 5 stars4.34.00.00.92.22.51.9JNJJohnson & Johnson4.5131 of 5 stars3.33.04.23.92.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOINCoinbase Global 2.68Moderate Buy$305.8994.49% UpsideCVNACarvana 2.67Moderate Buy$258.5954.30% UpsideJNJJohnson & Johnson 2.56Moderate Buy$171.3313.87% UpsideCurrent Analyst Ratings BreakdownLatest CVNA, COIN, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025COINCoinbase GlobalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$328.00 ➝ $169.004/4/2025CVNACarvanaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$250.00 ➝ $200.004/2/2025JNJJohnson & JohnsonRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/2/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/31/2025CVNACarvanaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight3/31/2025CVNACarvanaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Overweight3/27/2025CVNACarvanaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$365.00 ➝ $325.003/26/2025COINCoinbase GlobalRosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$305.00 ➝ $305.003/25/2025CVNACarvanaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$260.00 ➝ $280.003/20/2025COINCoinbase GlobalThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$195.003/20/2025CVNACarvanaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$225.00 ➝ $225.00(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOINCoinbase Global$6.56B6.08$5.33 per share29.52$40.48 per share3.89CVNACarvana$13.67B2.61$1.48 per share113.29$6.62 per share25.32JNJJohnson & Johnson$88.82B4.08$12.36 per share12.17$29.69 per share5.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOINCoinbase Global$2.58B$9.5016.5618.33N/A39.34%20.64%0.77%5/1/2025 (Estimated)CVNACarvana$450M$1.57106.7532.99N/A1.54%36.59%1.79%4/29/2025 (Estimated)JNJJohnson & Johnson$14.07B$6.6522.6313.592.5618.20%34.24%13.63%4/15/2025 (Estimated)Latest CVNA, COIN, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/ACOINCoinbase Global$2.18N/AN/AN/A$2.22 billionN/A4/15/2025N/AJNJJohnson & Johnson$2.59N/AN/AN/A$21.65 billionN/A2/19/2025Q4 2024CVNACarvana$0.2888$0.56+$0.2712$0.56$3.32 billion$3.55 billion2/13/2025Q4 2024COINCoinbase Global$0.46$3.39+$2.93$4.68$1.79 billionN/A1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOINCoinbase GlobalN/AN/AN/AN/AN/ACVNACarvanaN/AN/AN/AN/AN/AJNJJohnson & Johnson$4.963.30%+5.43%74.59%63 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOINCoinbase Global0.412.282.28CVNACarvana3.823.642.12JNJJohnson & Johnson0.431.110.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOINCoinbase Global68.84%CVNACarvana56.71%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipCOINCoinbase Global23.43%CVNACarvana17.12%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOINCoinbase Global4,510253.88 million191.69 millionOptionableCVNACarvana16,600213.17 million172.08 millionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableCVNA, COIN, and JNJ HeadlinesRecent News About These CompaniesSoutheast Asset Advisors LLC Sells 11,360 Shares of Johnson & Johnson (NYSE:JNJ)April 8 at 7:40 AM | marketbeat.comRathbones Group PLC Sells 224,058 Shares of Johnson & Johnson (NYSE:JNJ)April 8 at 7:22 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Employees Retirement System of TexasApril 8 at 6:29 AM | marketbeat.comJohnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)April 8 at 5:38 AM | globenewswire.comDynamic Technology Lab Private Ltd Purchases 1,957 Shares of Johnson & Johnson (NYSE:JNJ)April 8 at 5:28 AM | marketbeat.comJohnson & Johnson's Nipocalimab Shows Promising Results in Generalized Myasthenia Gravis StudyApril 8 at 5:25 AM | gurufocus.comJohnson & Johnson highlights new data, demonstrating long-term sustained disease control in adults living with generalised myasthenia gravis (gMG)April 8 at 3:30 AM | globenewswire.comJohnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)April 8 at 3:00 AM | prnewswire.comRep. Lloyd Doggett Buys Johnson & Johnson (NYSE:JNJ) StockApril 8 at 2:03 AM | marketbeat.comJohnson & Johnson (JNJ) Projected to Post Quarterly Earnings on TuesdayApril 8 at 1:28 AM | americanbankingnews.comJohnson & Johnson (JNJ) to Release Quarterly Earnings on TuesdayApril 8 at 1:28 AM | marketbeat.comJohnson & Johnson to Present at BofA Securities 2025 Healthcare ConferenceApril 7 at 5:56 PM | gurufocus.comJohnson & Johnson to Participate in the BofA Securities 2025 Healthcare ConferenceApril 7 at 4:25 PM | businesswire.comBig Pharma Stocks Dive Amid Trade War Jitters & Inflation WoesApril 7 at 9:40 AM | zacks.comU S Wealth Group LLC. Takes Position in Johnson & Johnson (NYSE:JNJ)April 7 at 7:21 AM | marketbeat.comLegal & General Group Plc Sells 4,603,436 Shares of Johnson & Johnson (NYSE:JNJ)April 7 at 7:16 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Bought by Invesco Ltd.April 7 at 7:13 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Fmr LLCApril 7 at 7:01 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Purchased by Prospector Partners LLCApril 7 at 6:59 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Acquired by Garrison Point Advisors LLCApril 7 at 6:53 AM | marketbeat.comBenchmark Investment Advisors LLC Sells 1,684 Shares of Johnson & Johnson (NYSE:JNJ)April 7 at 6:52 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBest of Both Worlds: 3 ETFs With High Dividend Yields, Low FeesBy Nathan Reiff | March 26, 2025View Best of Both Worlds: 3 ETFs With High Dividend Yields, Low FeesResilient Investing: 3 Stocks Built to Weather Market VolatilityBy Jeffrey Neal Johnson | March 17, 2025View Resilient Investing: 3 Stocks Built to Weather Market VolatilityCarMax and Carvana: Steering the Used Car MarketBy Jeffrey Neal Johnson | March 27, 2025View CarMax and Carvana: Steering the Used Car MarketARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?By Gabriel Osorio-Mazilli | March 18, 2025View ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?MicroStrategy Sees Insider Buy-Sell Action in Q1By Thomas Hughes | April 7, 2025View MicroStrategy Sees Insider Buy-Sell Action in Q1CVNA, COIN, and JNJ Company DescriptionsCoinbase Global NASDAQ:COIN$157.28 -3.27 (-2.04%) Closing price 04/7/2025 04:00 PM EasternExtended Trading$162.10 +4.82 (+3.06%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy in the United States and internationally. The company offers the primary financial account in the crypto economy for consumers; and a marketplace with a pool of liquidity for transacting in crypto assets for institutions. It also provides technology and services that enable developers to build crypto products and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.Carvana NYSE:CVNA$167.59 +5.02 (+3.09%) Closing price 04/7/2025 03:59 PM EasternExtended Trading$179.05 +11.46 (+6.84%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carvana Co., together with its subsidiaries, operates an e-commerce platform for buying and selling used cars in the United States. Its platform allows customers to research and identify a vehicle; inspect it using company's 360-degree vehicle imaging technology; obtain financing and warranty coverage; purchase the vehicle; and schedule delivery or pick-up from their desktop or mobile devices. The company also operates auction sites. The company was founded in 2012 and is based in Tempe, Arizona.Johnson & Johnson NYSE:JNJ$150.46 -2.78 (-1.81%) Closing price 04/7/2025 03:59 PM EasternExtended Trading$154.60 +4.14 (+2.75%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Springing Dividends: 3 Dividend Boosters to Watch Now Alibaba Caught in Tariff Crossfire: Is It Time to Buy? Can Solid Biosciences Challenge Sarepta in the DMD Market? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
